research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
Search
for
Sort by
Research
420-450 / 1000+ results
research A 5α-reductase inhibitor, finasteride, increases differentiation and proliferation of embryonal carcinoma cell-derived-neural cells
research Molecular Genetics of the PI3K-AKT-mTOR Pathway in Genodermatoses: Diagnostic Implications and Treatment Opportunities
The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
A cancer patient's hair became permanently curly after treatment with nivolumab.
research Reply to: “Tofacitinib for the treatment of severe alopecia areata and variants”
More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study
Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
research Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research Comparative Efficacy Evaluation of Alopecia Areata Management with Janus Kinase Inhibitors in Children: Retrospective Cohort Study
Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
research REV7: a small but mighty regulator of genome maintenance and cancer development
REV7 is crucial for genome stability and cancer treatment, making it a potential target for therapy.
research Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
Deucravacitinib helped a man regrow hair significantly.
research Tofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review
Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
research Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?
Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
research Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
RC48 shows promise for treating certain advanced cancers, but more research is needed.
research The Vitamin D Receptor as Tumor Suppressor in Skin
Vitamin D and its receptor may help prevent skin cancer.
research Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
The treatment is safe and shows promise for metastatic breast cancer.
research Nail, hair and skin hyperpigmentation associated with indinavir therapy
Indinavir therapy can cause reversible skin, hair, and nail darkening.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Prevention of erlotinib-induced folliculitis with doxycycline
Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research A new way to restore tumour suppressor function
New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.
research Scanning electron microscopy of ibrutinib-induced hair shaft changes
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Flutamide
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
![[4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) Inhibits SCF/c-kit Signaling in 501mel Human Melanoma Cells and Abolishes Melanin Production in Mice and Brownish Guinea Pigs](/images/research/4eb017dc-711d-4926-bcd0-c3b8f48e3a99/small/19974.jpg)
research [4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs
ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.
research Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy
EGFR inhibitors can cause yellowish skin eruptions.